Physician profile
Jeffrey M Wright
NPI 1285673715
$6,738.29
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $196 · 2021: $628 · 2022: $1,343 · 2023: $1,768 · 2024: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,547 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,546.50 |
| Education | $158.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,463.38 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,307.25 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $678.57 | 2019-2024 | Dupixent |
| Kaleo, INC. | $492.57 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $488.82 | 2021-2024 | |
| Csl Behring | $388.58 | 2019-2024 | Hizentra, Haegarda |
| Genentech USA, INC. | $259.93 | 2019-2024 | Xolair |
| Novartis Pharmaceuticals Corporation | $252.54 | 2019-2024 | |
| Optinose US, INC. | $234.13 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $158.98 | 2023-2024 | |
| Grifols USA, LLC | $148.57 | 2020-2024 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.87 | 2019-2021 | |
| Abbott Laboratories | $99.45 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abbvie INC. | $96.28 | 2023-2024 | Rinvoq |
| Pfizer INC. | $88.53 | 2022-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $77.12 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $47.03 | 2023 | Ryaltris |
| Bio Products Laboratory USA, INC. | $43.83 | 2023 | Coagadex, Gammaplex |
| Alk-Abello, INC | $43.23 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $41.86 | 2021 | |
| Amgen INC. | $39.17 | 2023 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $34.55 | 2024 | Cuvitru, Takhzyro |
| Kedrion Biopharma, INC. | $22.98 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Merck Sharp & Dohme LLC | $21.87 | 2019 | |
| Biocryst US Sales Co., LLC | $18.12 | 2022 | |
| Lilly USA, LLC | $17.82 | 2024 | Ebglyss, Zepbound |
| Aimmune Therapeutics, INC. | $15.18 | 2022 | |
| Mylan Specialty L.P. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.